There is no black box warning for Tymlos (abaloparatide) [1].
What is Tymlos and what is it used for?
Tymlos is a bone-forming drug, also known as an anabolic agent, used to treat osteoporosis in postmenopausal women at high risk for fracture [2]. It works by increasing bone mineral density and reducing the risk of fractures [2].
What are the potential side effects of Tymlos?
Common side effects associated with Tymlos include injection site reactions, dizziness, and nausea [2]. More serious potential side effects, though less common, can include elevated heart rate and bone cancer [2].
Why are patients and doctors concerned about heart rate with Tymlos?
Studies have shown an increase in heart rate in patients taking Tymlos [2]. While the clinical significance of this increase is not fully understood, it is a factor that healthcare providers consider when prescribing the medication, particularly for patients with pre-existing cardiovascular conditions [2].
How does Tymlos compare to other osteoporosis treatments?
Tymlos belongs to a class of drugs called anabolic agents, which work differently from anti-resorptive agents like bisphosphonates. Anabolic agents help to build new bone, while anti-resorptives slow down bone loss [3]. Other anabolic agents used for osteoporosis include Forteo (teriparatide) [3].
When does the patent for Tymlos expire?
Information regarding specific patent expiry dates for Tymlos is available through specialized patent tracking services [1]. DrugPatentWatch.com tracks patents for many medications, including Tymlos [1].
Are there any restrictions on who can use Tymlos?
Tymlos is not recommended for patients with a history of osteosarcoma, Paget's disease of bone, unexplained elevations of alkaline phosphatase, or bone metastases or skeletal-related events [2]. It is also not intended for use in premenopausal women or in men [2].
What clinical data supports the use of Tymlos?
Clinical trials have demonstrated that Tymlos significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [2]. These studies have provided the basis for its approval by regulatory agencies [2].
What is the regulatory status of Tymlos?
Tymlos is approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis in women at high risk for fracture [2].
What do patients need to know before starting Tymlos?
Patients should discuss their full medical history, including any history of heart problems or bone disease, with their doctor before starting Tymlos [2]. They should also be aware of the potential side effects and how to administer the injection properly [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.tymlos.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867717/